{"id":"W4394624476","doi":"10.1016/j.oret.2024.03.014","title":"Similar Risk of Kidney Failure among Patients with Blinding Diseases Who Receive Ranibizumab, Aflibercept, and Bevacizumab","year":2024,"lang":"en","type":"article","venue":"Ophthalmology Retina","topic":"Retinal Diseases and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Center for Advancing Translational Sciences; National Eye Institute; National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; U.S. National Library of Medicine; National Institute on Aging; National Institutes of Health; Janssen Research and Development; U.S. Department of Veterans Affairs","keywords":"Medicine; Ranibizumab; Aflibercept; Hazard ratio; Bevacizumab; Incidence (geometry); Internal medicine; Cumulative incidence; Ophthalmology; Surgery; Confidence interval; Cohort","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000771253,0.0003080296,0.0005418705,0.0001772523,0.0001187452,0.00003059478,0.00008320149,0.0001599048,0.0006690823],"category_scores_gemma":[0.0003035902,0.0002160996,0.0001570973,0.0002790117,0.0003946361,0.0001361801,0.00006926229,0.0002496428,0.00002296978],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006289465,"about_ca_system_score_gemma":0.0001287717,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005769337,"about_ca_topic_score_gemma":8.837638e-7,"domain_scores_codex":[0.9983861,0.000125879,0.0002961615,0.0005718179,0.0002856109,0.0003344423],"domain_scores_gemma":[0.998726,0.0001193614,0.0001437424,0.0003376647,0.0001294199,0.0005438603],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001544756,0.0003278879,0.9923646,0.0005308962,0.0004115561,0.001751184,0.0002243701,0.000001514396,0.00001229023,0.00003808115,0.001720423,0.0010724],"study_design_scores_gemma":[0.003056627,0.002084993,0.9905648,0.0009655708,0.001734713,0.000512898,0.0001525289,0.00007835404,0.00006888375,0.0002584557,0.000311339,0.0002108958],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9937558,0.001292354,0.000004282746,0.0002784467,0.0001059585,0.000649212,0.0004864428,0.00006204778,0.003365459],"genre_scores_gemma":[0.9982589,0.0001143958,0.0003374522,0.00003813869,0.00005711778,0.00003892939,0.0003189197,0.0000566097,0.0007795335],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004503106,"threshold_uncertainty_score":0.8812286,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.005561132180104783,"score_gpt":0.2464766331168076,"score_spread":0.2409155009367029,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}